We're building the next generation laboratory for drug design

Unleashing Chemical Intelligence

Discover more

About

At InVirtuoLabs, we are revolutionizing drug discovery by seamlessly integrating cutting-edge artificial intelligence with molecular simulations. Our innovative platform combines advanced machine learning techniques—including multimodal learning, active learning, and generative chemistry—with physics-based simulations to explore vast chemical spaces with unprecedented efficiency.

By leveraging this powerful synergy, we are able to rapidly identify and optimize promising drug candidates, dramatically accelerating the path from concept to life-changing therapies.

Next Generation Lab

Icon of User Circle Check
Proprietary Drug Discovery Projects
Icon of Microscope
Next Generation Virtual Laboratory
Icon of Circuitry
Co-Development with Pharma
Boldbrain Logo

Boldbrain 2024 Winners

Discover more

A modular solution to explore the deep chemical universe

InVirtuoMOL

Molecular ML engine

InVirtuoGEN

Multimodal generative AI

InVirtuoSIM

Physics-based simulations

Cutting-edge machine learning methods to swiftly evaluate a comprehensive range of critical properties for potential drug candidates. This innovative tool provides rapid, in-depth assessments of molecular properties, empowering our researchers to make data-driven decisions early in the design process.

By accelerating the identification of promising therapeutic compounds and enhancing the overall efficiency of drug discovery, our technology paves the way for faster development of innovative treatments.

90% reduction in processing time.

Our drug discovery pipeline

Target Validation
Hit Discovery
Lead Optimization
Preclinical Validation
Phase I, II, III
Neurological Disorders
IVL-001
Neurological Disorders
IVL-002
Oncology
IVL-003
Metabolic Disorders
IVL-004

AI-Discovered drugs already have lower risk of failure

Success probability across clinical stages[1]

5-10%
Historic industry average
VS
9-18%
AI-discovered molecules

Generative AI is about reshaping the way we design drugs

50%
Time and cost savings[2]
200%
Predictive Model Performance[2]
400%
Speed of discovery[3]

Supported by

Our Team

Gianvito Grasso Photo

Gianvito Grasso, PhD

Linkedin

Chief Executive Officer

Biomedical Engineer with a PhD in Computational Science. 10+ years as a researcher in the field of molecular simulations and machine learning. Principal Investigator of several national and international research projects.

Sertac Yeltekin Photo

Sertac Yeltekin

Linkedin

Chief Operating Officer

30+ years of international experience in a wide array of managerial roles in the corporate and consulting universe. Expert in venture building and business development as investor, founder and ecosystem builder.

Stefano Muscat Photo

Stefano Muscat, PhD

Linkedin

Molecular Modeling and Simulations

Biomedical Engineer with a PhD in Informatics. Expert in integrating enhanced molecular simulations for drug design applications.

Demet Olesen Photo

Demet Olesen

Linkedin

Chief Commercial Officer

+25 years of experience as a pharma executive in CrossOver, PTC Therapeutics, Baxter, Pharma Nord, Novo Nordisk and Pfizer in Europe, Turkey and the USA.

Francesco Gentile Photo

Francesco Gentile, PhD

Linkedin

AI for chemistry

AI for chemistry expert with 10+ years of experience in computer-aided drug discovery. Contributed to the development of several drug candidates for cancer, viral infections, and neurodegenerative diseases.

Claudio Pietra Photo

Claudio Pietra

Linkedin

Chief Scientific Officer

30+ years in preclinical research and development. Former Director and Head of Innovation at Helsinn Healthcare SA. He worked in several pharmaceutical companies, including Recordati, Chiesi Pharmaceutical, and Glaxo Wellcome.

Benno Käch  Photo

Benno Käch, PhD

Linkedin

Generative Chemistry

Machine Learning Researcher with a PhD in particle physics and expertise in generative modeling, statistical analysis, and machine learning

Lorenzo Pallante Photo

Lorenzo Pallante, PhD

Linkedin

Molecular Modelling and Machine Learning

Biomedical engineer with a strong background in molecular modelling for understanding biological mechanisms and machine learning for predicting molecular properties.

Nicolai Olesen Photo

Nicolai Olesen

Linkedin

Development & Operations Engineer

Biomedical engineer with a strong background in signal processing, software engineering and biomedical instrumentation.

Strategic Advisors

Prof. Jack A. Tuszynski Photo

Prof. Jack A. Tuszynski, PhD

Linkedin
Pioneering scientist and professor in computational drug discovery with over 500 scientific publications and 4 patents in the USA, Japan, and Singapore, and developer of a drug candidate currently in clinical trials.
Diego Piovan Photo

Diego Piovan

Linkedin
30+ years in large companies across different technology sectors, with a strong track record in management and AI strategy implementation. Former Deloitte Partner, Banking COO, Bain & Co Manager.
Baris Bilen Photo

Baris Bilen

Linkedin
25+ years of entrepreneurial experience, mostly in food technology with R&D intensive products and international business development. Chemical engineering degree from Bosphorous University and MBA from Columbia Business School.
Marco Tosoni Photo

Marco Tosoni

Linkedin
Marco is a software engineer by education who worked in the Tech sector for 20+ years, specializing in product and program management roles. In his career, he served as an advisor for multiple tech startups, led the global program management organization at Kraken and spent 9 years at Google contributing to multiple products and infrastructure systems.
Dr. Giacomo Di Benedetto Photo

Giacomo Di Benedetto, PhD

Linkedin
Serial entrepreneur in the biotech field, PhD in Biomedical Engineering. Secured over €6 million from private and public investors and international funding tenders.
Maria Veronika Stattin Photo

Maria Veronika Stattin

Linkedin
5+ years of experience in biotech industry in consulting (BCG) and Business development (Regeneron). BA in Neuroscience from Columbia University and an MBA in Finance and Heath care management from Wharton.
Alessandro Grande Photo

Alessandro Grande

Linkedin
Solution Architect & AWS Practice Lead at Claranet Italia, certified in AWS, with over a decade of experience in cloud and on-premise infrastructure. Specializes in developing architectural solutions and optimizing enterprise cloud implementations, emphasizing best practices and client collaboration. Co-founder of AWS User Group Salento, actively contributing to the tech community through speaking engagements and workshops.

Contact us if you would like to get to know In Virtuo Labs better

6900 - Lugano (CH)